Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine

European Journal of Cancer

Volumn 34, Issue 13, 1998, Pages 2129-2131

  Seeber, A ^a   Binder, M ^a   Steiner, A ^a   Wolff, K ^a   Pehamberger, H ^a  

^a NONE

Author keywords

Chemotherapy; Dacarbazine; Malignant melanoma; Metastatic disease

Indexed keywords

DACARBAZINE; FOTEMUSTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0032403573     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00316-5     Document Type: Article

References (13)

1. 1. Ho RC. Medical management of stage IV malignant melanoma. Medical issues. Cancer 1995, 75(Suppl.), 735-741.
2. 2. Avril MF, Bonneterre J, Cupissol D, et al. Fotemustine and dacarbazine for malignant melanoma. Eur J Cancer 1992, 28A, 1807-1811.
3. 3. Amdal S, Gerard B, Bohman T, D'Incalci M. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma - an effective combination with unexpected toxicity. Eur J Cancer 1992, 28A, 447-450.
4. 4. Binder M, Winkler A, Dorffner R, Glebowski E, Wolff K, Pehamberger H. Fotemustine plus dacarbazine in advanced stage III malignant melanoma. Eur J Cancer 1992, 28A, 1814-1816.
5. 5. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organisation, Geneva, 1979.
6. 6. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosurea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990, 66, 1873-1878.
7. 7. Merimsky O, Inbar M, Chaitchik S. Fotemustine and DTIC combination in patients with disseminated malignant melanoma. Am J Clin Oncol 1992, 15, 84-86.
8. 8. Oliver V, Aliaga A, Lopez Lpez JJ, et al. Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine. Eur J Cancer 1993, 29A, 287.
9. 9. Lee SM, Thatcher N, Dougal M, Margison GP. Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 1993, 67, 216-221.
10. 10. Lee SM, Margison GP, Woodcock AA, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993, 67, 1356-1360.
11. 11. Gerard B, Aamdal S, Lee SM, et al. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine - in patients with melanoma. Eur J Cancer 1993, 29A, 711-719.
12. 12. Chang J, Atkinson H, A'Hern R, Lorentzos A, Gore ME. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur J Cancer 1994, 30A, 2093-2095.
13. 13. Kleeberg UR, Engel E, Israels P. Palliative therapy of melanoma with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicenter phase II trial of the EORTC - Melanoma Cooperative Group (MCG). Melanoma Res 1995, 5, 195-200.